English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/214590
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Comparison of antibiotic treatment guidelines for urinary tract infections in 15 European countries: Results of an online survey

AuthorsMalmros, Karin; Huttner, B. D.; McNulty, Cliodna; Rodríguez-Baño, Jesús; Pulcini, Céline; Tängdén, Thomas
KeywordsUrinary tract infection
Guidelines
Antimicrobial stewardship
AMS
Antimicrobial resistance surveillance
Antibiotic availability
Issue DateOct-2019
PublisherElsevier
CitationInternational Journal of Antimicrobial Agents 54(4): 478-486 (2019)
AbstractAppropriate antibiotic use for urinary tract infections (UTIs) is important in order to provide effective and safe treatment while minimising the risk of antimicrobial resistance development. This survey was carried out to compare existing national guidelines for UTIs in Europe. Experts in 37 European countries were asked to participate. An electronic questionnaire was used to obtain information on treatment recommendations, factors considered important when setting guidelines, acceptable resistance rates for empirical therapy, evidence grading, and existing resistance surveillance for uropathogens. Treatment guidelines and antimicrobial susceptibility data were collected. In total, 22 experts (59%) responded to the survey. National guidelines were missing in four countries and data were incomplete in three cases. Fifteen national guidelines published between 2004 and 2017 were included in the analysis. Great variability was found between guidelines in the selection of antibiotics, dosing regimens and treatment duration. For example, 10 different antibiotics were recommended as first-line therapy for uncomplicated cystitis. National surveillance data on antimicrobial susceptibility of uropathogens were available in 13 of 15 countries. Resistance epidemiology could not explain the observed differences between guidelines, and comparison of resistance rates was hampered by variations in methods. This study revealed major differences in treatment guidelines for UTIs within Europe, indicating that there are opportunities for improvement. More clinical research and a more systematic and stratified approach to resistance surveillance, including also antibiotics that are currently not available in all countries, is needed.
Publisher version (URL)http://dx.doi.org/10.1016/j.ijantimicag.2019.06.015
URIhttp://hdl.handle.net/10261/214590
DOIhttp://dx.doi.org/10.1016/j.ijantimicag.2019.06.015
ISSN0924-8579
E-ISSN1872-7913
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.